Last €36.33 EUR
Change Today +0.094 / 0.26%
Volume 10.0
MYL On Other Exchanges
Symbol
Exchange
Munich
As of 4:04 AM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

mylan inc (MYL) Snapshot

Open
€35.82
Previous Close
€36.24
Day High
€36.33
Day Low
€35.82
52 Week High
03/5/14 - €41.98
52 Week Low
05/3/13 - €20.81
Market Cap
13.5B
Average Volume 10 Days
423.0
EPS TTM
--
Shares Outstanding
371.9M
EX-Date
07/17/07
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MYLAN INC (MYL)

mylan inc (MYL) Details

Mylan Inc., a pharmaceutical company, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch form, as well as active pharmaceutical ingredients (APIs). This segment is also involved in developing APIs with non-infringing processes to partner with manufacturers; and the manufacture and sale of injectable products in the therapeutic areas of antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular. In addition, it produces finished dosage form (FDF) products for the antiretroviral (ARV) market and non-ARV FDF products that are marketed to third parties. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector for the treatment of severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. It also offers ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. to develop, manufacture, distribute and market generic drugs in Japan. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

20,000 Employees
Last Reported Date: 02/27/14
Founded in 1961

mylan inc (MYL) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.1M
President, Director and Member of Science & T...
Total Annual Compensation: $840.4K
Executive Chairman and Chairman of Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $650.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $575.0K
Compensation as of Fiscal Year 2013.

mylan inc (MYL) Key Developments

FDA Approves Mylan, Inc.'s XULANE (Norelgestromin/Ethinyl Estradiol Transdermal System 150/35 mcg per day) for the Prevention of Pregnancy

Mylan, Inc. revealed the market launch of its US Food and Drug Administration (FDA) approved XULANE (Norelgestromin /Ethinyl Estradiol Transdermal System 150/35 mcg per day). This launch has been initiated by the company's US based subsidiary, Mylan Pharmaceuticals. The company added XULANE (Norelgestromin /Ethinyl Estradiol Transdermal System 150/35 mcg per day) is the generic version of Janssen Pharmaceuticals' ORTHO EVRA (Norelgestromin /Ethinyl Estradiol Transdermal System 150/35 mcg per day). XULANE is reportedly indicated for the prevention of pregnancy in women who elect to use a transdermal patch as a method of contraception.

Mylan, Inc. Launches Generic Lunesta Tablets

Mylan Inc. announced that it has launched Eszopiclone Tablets 1 mg, 2 mg and 3 mg, the generic version of Sunovion Pharmaceuticals Inc.'s Lunesta. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated for the treatment of insomnia. Currently, Mylan has 187 ANDAs pending FDA approval representing $94.9 billion in annual brand sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $25.4 billion in annual brand sales, for the 12 months ending Dec. 31, 2013, according to IMS Health. When including ANDAs associated with Mylan's recent acquisition of Agila, the company now has a total of 304 ANDAs pending FDA approval.

Actavis Announces Agreement Related to Generess FE Patent Challenge Litigation

Actavis plc announced that it has entered into an agreement with Mylan Inc. and Famy Care Ltd. to settle all outstanding patent litigation related to Mylan's generic version of Generess(R) FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets). Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess(R) FE under its pending Abbreviated New Drug Application (ANDA) beginning on April 1, 2015. Alternatively, Mylan will be permitted to launch an authorized generic version of Actavis' product beginning on October 1, 2015. Other terms of the settlement were not disclosed. Actavis remains in litigation with Lupin Ltd. in connection with Lupin's pending ANDA for a generic version of Generess(R).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:GR €36.33 EUR +0.094

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Forest Laboratories Inc $91.65 USD -0.48
Grifols SA €38.30 EUR +0.37
Perrigo Co PLC $149.93 USD -1.62
Sun Pharmaceutical Industries Ltd 625.60 INR +5.65
UCB SA €59.67 EUR +0.13
View Industry Companies
 

Industry Analysis

MYL

Industry Average

Valuation MYL Industry Range
Price/Earnings 31.5x
Price/Sales 2.7x
Price/Book 6.3x
Price/Cash Flow 29.7x
TEV/Sales 1.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN INC, please visit www.mylan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.